ArticleCancer immunology, immunotherapy : CII2026
Compartment-specific GLUT1 patterns in colorectal liver metastases: invasive-margin GLUT1 associates with outcome in solitary disease.
Article in Cancer immunology, immunotherapy : CII, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundColorectal liver metastases (CRLM) are a major cause of cancer-related deaths. Glucose transporter 1 (GLUT1) is a key mediator of glycolytic metabolism in malignant and immune cells; however, the prognostic relevance of compartment-specific GLUT1 patterns in CRLM remains undefined. We hypothesized that spatial GLUT1 expression at the tumor-liver interface may reflect clinically relevant microenvironmental biology.
methodsWe retrospectively analyzed data of 192 patients who underwent curative-intent resection for CRLM (75 solitary; 117 multiple). GLUT1 expression was assessed by immunohistochemistry in the tumor tissue (Tu) and infiltration margin (Im) and was correlated with overall survival using Cox regression. Double immunofluorescence for CD8 and GLUT1 was performed for qualitative visualization at the infiltration margin. In an exploratory subset (n = 5), flow cytometry and in vitro killing assays were conducted on GLUT1⁺ versus GLUT1⁻ CD8⁺ tumor-infiltrating lymphocytes (TILs).
resultsTumoral GLUT1 correlated with Ki67 (Spearman's ρ = 0.31, p = 0.003) but was not independently associated with overall survival in the main cohort (multivariable HR 1.183, 95% CI 0.74-1.90; p = 0.485). In the main cohort, capsule presence remained strongly associated with improved survival (HR 0.35, 95% CI 0.21-0.58; p < 0.001). In contrast, high invasive-margin GLUT1 was independently associated with improved survival in the predefined solitary cohort (HR 0.379, 95% CI 0.18-0.81; p = 0.012). Double immunofluorescence demonstrated the qualitative co-localization of the GLUT1 signal with CD8⁺ cells at the infiltration margin. In exploratory assays (n = 5), flow cytometry suggested GLUT1 enrichment in CD8⁺ terminally differentiated effector memory T cells re-expressing CD45RA (TEMRA), and GLUT1⁺ TIL fractions showed higher in vitro tumor cell killing compared with GLUT1⁻ cells.
conclusionGLUT1 shows compartment- and context-dependent associations in the CRLM. While tumor-core GLUT1 is linked to proliferative activity, invasive-margin GLUT1 is associated with favorable outcomes in solitary metastases. Immunofluorescence and functional data provide hypothesis-generating context and warrant validation with quantitative spatial immune profiling and independent cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.